Novartis (NVS)
(Delayed Data from NYSE)
$113.77 USD
-0.09 (-0.08%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $113.76 -0.01 (-0.01%) 6:24 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.77 USD
-0.09 (-0.08%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $113.76 -0.01 (-0.01%) 6:24 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
A Day of Mergers: TIF, AMTD, MDCO & More
by Zacks Equity Research
A Day of Mergers: TIF, AMTD, MDCO & More
Biggest Merger Monday in Awhile: TIF, AMTD, MDCO & More
by Mark Vickery
While Tiffany's agrees to terms with French luxury brand LVMH, Schwab buys Ameritrade, Novartis takes Medicines Co. and more.
Novartis (NVS) to Acquire The Medicines Company for $9.7B
by Zacks Equity Research
Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
The Medicines Company to be Acquired by Novartis for $9.7B
by Zacks Equity Research
The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.
Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes
by Kinjel Shah
The FDA approves Novartis' (NVS) sickle cell disease candidate Adakveo and AstraZeneca's (AZN) Calquence for chronic lymphocytic leukemia. Bristol-Myers (BMY) completes $74 billion-buyout of Celgene.
Medicines Company Up on Rumors of Potential Buyout by Novartis
by Zacks Equity Research
The Medicines Company (MDCO) is rumored to attract acquisition offers after impressive data readouts from three pivotal studies on PCSK9 inhibitor candidate, inclisiran.
Merck's Heart Failure Candidate Meets Goal in Phase III Study
by Zacks Equity Research
Merck (MRK) and German partner Bayer's vericiguat reduces the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure.
Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex
by Zacks Equity Research
Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.
Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease
by Zacks Equity Research
Novartis (NVS) gets FDA nod for Adakveo to reduce the frequency of pain crises in adult and pediatric SCD patients.
Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe
by Zacks Equity Research
Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Novartis (NVS) and Novo Nordisk (NVO).
Roche's SMA Drug Meets Primary Endpoint in Pivotal Study
by Zacks Equity Research
Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day
Novartis' Generics Unit to Buy Aspen's Japanese Operations
by Zacks Equity Research
Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.
Tilray (TLRY) Set to Report Q3 Results: Will the Stock Continue to Plunge?
by Christopher Vargas
Tilray (TLRY) is set to report its third quarter results after the closing bell Tuesday, November 12.
Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
by Kinjel Shah
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) incurs narrower loss in Q3. Sales of Nerlynx decline sequentially. Stock drops 18%.
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
by Zacks Equity Research
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales
by Zacks Equity Research
Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.
Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.
Has Novartis (NVS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVS) Outperforming Other Medical Stocks This Year?